确定一线HR+/HER2-转移性乳腺癌治疗选择的驱动因素
Adam Brufsky1, Martine C Maculaitis2, Lewis Kopenhafer2
1University of Pittsburgh School of Medicine, Pittsburgh, PA USA.
Future oncology (London, England)
|June 11, 2024
概括
在选择HR+/HER2-转移性乳腺癌的第一线治疗方法时,瘤学家优先考虑疗效和安全性. 患者的人口结构和临床因素影响选择CDK4/6抑制剂,化疗或芳酶抑制剂单疗.
科学领域:
- 在瘤学瘤学.
- 医疗治疗 医疗治疗
背景情况:
- 激素受体阳性/人体表皮生长因子受体2-阴性 (HR+/HER2-) 转移性乳腺癌的第一线 (1L) 治疗选择是复杂的.
- 了解影响这些关键治疗决策的因素对于优化患者的治疗结果至关重要.
研究的目的:
- 在美国瘤学家中评估与对HR+/HER2-转移性乳腺癌的第一线 (1L) 治疗选择相关的关键因素.
主要方法:
- 对250名美国瘤学家进行了横截面调查.
- 分析了治疗类 (例如CDK4/6抑制剂,化疗,芳香酶抑制剂) 和各种患者和临床特征之间的相关性.
主要成果:
- 有效性和安全性/耐受性被确定为1L治疗决策中最关键的因素.
- 循环素依赖性激酶4/6抑制剂 (CDK4/6i) 的使用与医疗保险患者和绝经后状态相关.
- 化疗使用与绝经前/绝经前患者和更高的症状负担有关.
- 芳香酶抑制剂 (AI) 单疗与预期的治疗顺应性相关.
结论:
- 在为HR+/HER2-转移性乳腺癌选择一线疗法时,有效性和安全性仍然至关重要.
- 具体的临床特征与使用CDK4/6抑制剂和化疗相一致.
- 预期的患者服从是与使用人工智能单疗法相关的一个显著因素.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


